Literature DB >> 22658713

Type I immune response cytokine-chemokine cascade is associated with pulmonary arterial hypertension.

David J Ross1, Robert M Strieter, Michael C Fishbein, Abbas Ardehali, John A Belperio.   

Abstract

BACKGROUND: Perivascular infiltrating mononuclear cells have been described in the vasculopathy found in multiple types of pulmonary arterial hypertension (PAH). We determined the expression of a specific type 1 immune response cytokine-chemokine cascade-interleukin (IL)-18 → (monokine induced by γ-interferon [MIG]/chemokine [C-X-C motif] ligand [CXCL] 9, interferon γ-induced protein [IP]-10/CXCL10 and interferon-inducible T-cell α chemoattractant [ITAC]/CXCL11)-in plasma samples from individuals with World Health Organization (WHO) Group 1 PAH.
METHODS: We analyzed cytokine and chemokine protein levels in plasma from 43 individuals with WHO Group 1 PAH by enzyme-linked immunosorbent assay compared with 35 healthy individuals. Immunohistochemical studies on tissue specimens from WHO Group 1 PAH patients were performed for cytokines and chemokines and their respective receptors.
RESULTS: Plasma IL-18 levels from WHO Group 1 PAH patients were significantly increased compared with healthy controls. Downstream chemokine CXCL10, but not CXCL9 or CXCL11, was markedly elevated compared with controls. Cellular sources of IL-18 were medial but not intimal smooth muscle cells. IL-18Rα was expressed from medial smooth muscle cells, endothelial cells, and mononuclear cells. CXCL10 and its main receptor, CXCR3, were expressed from infiltrating vascular wall mononuclear cells.
CONCLUSIONS: These data suggest that augmented expression of IL-18 and CXCL10 may perpetuate an inflammatory milieu that eventually contributes to the vascular obstruction characteristic of PAH.
Copyright © 2012 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22658713     DOI: 10.1016/j.healun.2012.04.008

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  23 in total

1.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Inflammasomes: a novel therapeutic target in pulmonary hypertension?

Authors:  Tara Elizabeth Scott; Barbara K Kemp-Harper; Adrian J Hobbs
Journal:  Br J Pharmacol       Date:  2018-06-27       Impact factor: 8.739

4.  Abnormal Glucose Metabolism and High-Energy Expenditure in Idiopathic Pulmonary Arterial Hypertension.

Authors:  Gustavo A Heresi; Steven K Malin; Jarrod W Barnes; Liping Tian; John P Kirwan; Raed A Dweik
Journal:  Ann Am Thorac Soc       Date:  2017-02

5.  BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.

Authors:  Leanda Vengethasamy; Aurélie Hautefort; Birger Tielemans; Catharina Belge; Frédéric Perros; Stijn Verleden; Elie Fadel; Dirk Van Raemdonck; Marion Delcroix; Rozenn Quarck
Journal:  Pflugers Arch       Date:  2016-11-06       Impact factor: 3.657

6.  Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension.

Authors:  David J Ross; Greg Hough; Susan Hama; Jamil Aboulhosn; John A Belperio; Rajan Saggar; Brian J Van Lenten; Abbas Ardehali; Mansoureh Eghbali; Srinivasa Reddy; Alan M Fogelman; Mohamad Navab
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

Review 7.  Update on novel targets and potential treatment avenues in pulmonary hypertension.

Authors:  John C Huetsch; Karthik Suresh; Meghan Bernier; Larissa A Shimoda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-02       Impact factor: 5.464

8.  Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension.

Authors:  Andrew J Sweatt; Haley K Hedlin; Vidhya Balasubramanian; Andrew Hsi; Lisa K Blum; William H Robinson; Francois Haddad; Peter M Hickey; Robin Condliffe; Allan Lawrie; Mark R Nicolls; Marlene Rabinovitch; Purvesh Khatri; Roham T Zamanian
Journal:  Circ Res       Date:  2019-03-15       Impact factor: 17.367

Review 9.  Dust events, pulmonary diseases and immune system.

Authors:  Nafiseh Esmaeil; Marjan Gharagozloo; Abbas Rezaei; Gabriele Grunig
Journal:  Am J Clin Exp Immunol       Date:  2014-02-27

10.  KCNK3 Mutation Causes Altered Immune Function in Pulmonary Arterial Hypertension Patients and Mouse Models.

Authors:  James D West; Eric D Austin; Elise M Rizzi; Ling Yan; Harikrishna Tanjore; Amber L Crabtree; Christy S Moore; Gladson Muthian; Erica J Carrier; David A Jacobson; Rizwan Hamid; Peggy L Kendall; Susan Majka; Anandharajan Rathinasabapathy
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.